Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.

EDWARDS INTUITY Elite valve system. Indications: The EDWARDS INTUITY Elite valve is indicated for the replacement of diseased, damaged or malfunctioning native or prosthetic aortic valves.

Communicate with your doctor so you can be aware of the considerations that come with your valve choice and how they might affect your post-surgery lifestyle. Today, there are several treatment options for valvular heart disease (VHD), including medications, heart valve repair, or valve replacement.

The INSPIRIS RESILIA aortic valve, model 11500A, is a stented trileaflet valve comprised of RESILIA bovine pericardial tissue that is mounted on a flexible frame.

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]

The Edwards SAPIEN 3 Ultra transcatheter heart valve is comprised of a balloon-expandable, radiopaque, cobalt-chromium frame, trileaflet bovine pericardial tissue valve, and polyethylene terephthalate (PET) inner and outer fabric skirts.

Nov 25, 2024 · Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

The EDWARDS INTUITY Elite valve system consists of the EDWARDS INTUITY Elite valve, model 8300AB and the EDWARDS INTUITY Elite delivery system, model 8300DB. The pericardial stented aortic valve is based on the design and the proven performance of the PERIMOUNT valve family.

Nov 25, 2024 · As a leader in heart valves for over 60 years, Edwards Lifesciences is dedicated to providing you a destination for the latest transcatheter heart valve information, tools, resources, and innovative solutions.

* The PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVI with the SAPIEN 3 valve, AT population (n=1077). The clear choice for your patients and your TAVI program.